We're thrilled to announce Soleno Therapeutics as our Platinum Sponsor for the 6th Asia Pacific PWS Conference.
Hear an update from Soleno Therapeutics accross both days about their work with DCCR to treat hyperphagia in Prader-Willi Syndrome.
Soleno Therapeutics, Inc. (Soleno) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Our first priority is Prader-Willi syndrome (PWS), a rare and life-threatening neurobehavioral, metabolic, and endocrine disorder characterized by hyperphagia (insatiable hunger), neurocognitive, and behavioral difficulties. We are dedicated to bringing the first approved treatment to individuals with PWS to manage the most burdensome aspects of this devastating disorder. For more information, please visit www.soleno.life.
Hear from our gold sponsor, Aardvark Therapeutics for the 6th Asia Pacific PWS Conference.
In an Australian first, join us to hear directly from CEO of Aardvark therapeutics, Tien Lee M.D will discuss Aardvark’s lead compound, oral ARD-101. ARD-101 has demonstrated an ability to reduce hunger when used alone or in combination with currently available GLP-1 therapies. Based on promising clinical data from an ongoing ARD-101 trial, the FDA has granted the drug both Orphan Drug designation and Rare Pediatric Rare Disease designation in PWS.
Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, inflammation, and other indications. Aardvark’s lead compound, oral ARD-101, is a potent bitter taste receptor (TAS2R) pan-agonist that stimulates enteroendocrine cells of the digestive tract to release multiple gut-peptide hormones including GLP-1 and the satiety hormone Cholecystokinin (CCK), which activates gut-brain neurologic signaling to mediate hunger. ARD-101 has demonstrated an ability to reduce hunger when used alone or in combination with currently available GLP-1 therapies. Based on promising clinical data from an ongoing ARD-101 trial, the FDA has granted the drug both Orphan Drug designation and Rare Pediatric Rare Disease designation in PWS.
Don't miss out on this incredible opportunity to learn from Aardvark Therapeutics and other industry leaders at the 6th Asia Pacific PWS Conference.
Breakthroughs that change patients’ lives™
Throughout Pfizer's 175 year history, and over 60 years in Australia, we have remained dedicated to discovering and developing new and better ways to prevent and treat disease, and improve the health and wellbeing of people around the world.
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global health care portfolio includes human biologic and small molecule medicines and vaccines.
For more information visit www.pfizer.com.au
Interaction Disability Services is a not-for-profit, NDIS-registered organisation committed to supporting and empowering people living with intellectual disability. Interaction Services was founded in 1979 by a group of parents with a plan for their children with disability to integrate into the community and transition into independent living. Early efforts focused on the transition from the family home into an intensive skill development program supported by families and volunteers. Empowering people through education and community networks, people were then transitioned to independent accommodation with minimal assistance. Over the last 40 years, we’ve built on their vision and have expanded to support more than 550 families and individuals annually.
Interaction works with individuals and families across NSW including participants with intellectual and/or physical disability, and families and carers of people with disability. In addition to our general support services, Interaction is proud to be a best practice provider of specialist support for people with Prader-Willi Syndrome (PWS). In 1992, Interaction established the first accommodation program in Australia designed to meet the specific needs associated with PWS. Since then, we have continued to work with individuals and families to provide a range of PWS supports.
Interaction provides the following supports to children, adults and their families.
Supported Accommodation
Support Coordination
Community Access and Self Care
Behaviour and Allied Health Services
Activities and Events
Our support services are available across the Greater Sydney, Central Coast and Newcastle regions of NSW and available to people of any age, ability, need or background. We value diversity and understand that no two people are the same. This is why we work closely with people to build flexible and practical supports that meet their individual needs.
At Interaction, our mission is to provide exceptional services for people with disability, primarily those with an intellectual disability, and their support networks. Through person-centred support, we empower people to reach their individual goals and aspirations.
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that when empathy and innovation meet, a better life can begin for people living with neurological diseases. Our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for patients, who are at the heart of everything we do.
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years, we have been working at the forefront of healthcare to bring vital solutions to people who need them most.
Proudly Sponsored by,
